Menu
1-702-720-6310 info@microcapspecualtors.com

Why Celgene’s $413 Million Gamble Helps This Small Biotech More – Investor’s Business Daily


Investor’s Business Daily

Why Celgene’s $413 Million Gamble Helps This Small Biotech More
Investor’s Business Daily
Chinese biotech BeiGene (BGNE) is the strongest beneficiary of Celgene’s (CELG) $413 million gamble in immuno-oncology, an analyst said Friday as BeiGene stock touched a fresh high. Under the terms of the deal, BeiGene obtained the rights to …

and more »

Search